Some conditions respond to intravenous vaccinia immunoglobulin (IV-VIG), including eczema vaccinatum, progressive vaccinia, severe ocular vaccinia, severe generalized vaccinia. IV-VIG is not effective in treating post-vaccinial encephalitis.
IV-VIG consists of human IgG antibody from people vaccinated with smallpox vaccine. Current supplies of IV-VIG are limited.
Once a definite or probable diagnosis of a medication-indicating adverse event has been made by a qualified provider (e.g., infectious-disease, dermatology, allergy-immunology physician), that military provider may request use of IV-VIG for a named patient by telephoning the Military Vaccine Agency - Vaccine Healthcare Centers Network at 877-GET-VACC, DSN 761-4245, email DoDVaccines@mail.mil. Procedures for ordering IV-VIG appear at www.smallpox.mil/documents/1101MIP-VIG-ordering-infoNo07.pdf. Healthcare providers from civilian institutions should contact the CDC directly by calling the CDC Director's Emergency Operation Center (DEOC) at (770) 488-7100 and request to speak with the Division of Bioterrorism Preparedness and Response (DBPR) on-call person. The CDC is the release authority for IV-VIG.